Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14896145 | 0.90 | HDAC6 (0.55) | HDAC6HDAC1HDAC10 | |
| SCHEMBL14896021 | 0.87 | HDAC1 (0.49) | HDAC6HDAC1HDAC10 | |
| SCHEMBL14893963 | 0.84 | HDAC6 (0.78) | HDAC6HDAC1CNR2HDAC10 | |
| SCHEMBL14893720 | 0.84 | HDAC6 (0.53) | HDAC6HDAC1CNR2HDAC10 | |
| SCHEMBL14896109 | 0.81 | HDAC6 (0.52) | HDAC6HDAC1CNR2HDAC10 | |
| SCHEMBL14896317 | 0.78 | HDAC1 (0.58) | HDAC6HDAC1CNR2 | |
| SCHEMBL14895937 | 0.77 | HDAC6 (0.75) | HDAC6HDAC1CNR2HDAC10 | |
| SCHEMBL14895799 | 0.76 | BRD4 (0.55) | HDAC6HDAC1 | |
| SCHEMBL1002975 | 0.76 | HDAC6 (0.67) | HDAC6HDAC1CNR2HDAC10DRD2 | |
| SCHEMBL5438238 | 0.75 | P2RX4 (0.66) | HDAC6HDAC1CNR2HDAC10DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315889-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-10-23 | — | — | US | disclosed |
| US-20140315889-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-10-23 | — | — | US | disclosed |
| US-20140315889-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-10-23 | — | — | US | disclosed |
| EP-2771321-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | Chong Kun Dang Pharmaceutical Corp. (KR) | 2014-09-03 | — | — | EP | disclosed |
| WO-2013062344-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013062344-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315889-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | HDAC1, HDAC5, HDAC3 | HDAC6 8/4885HDAC1 1/4885CNR2 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.